Document is current
Any future updates will be listed below
-
Authors
Ranson, Janice M.
Rittman, Timothy
Hayat, Shabina
Brayne, Carol
Jessen, Frank
Blennow, Kaj
van Duijn, Cornelia
Barkhof, Frederik
Tang, Eugene
Mummery, Catherine J.
Stephan, Blossom C. M.
Altomare, Daniele https://orcid.org/0000-0003-1905-8993
Frisoni, Giovanni B.
Ribaldi, Federica
Molinuevo, José Luis
Scheltens, Philip
Llewellyn, David J.
,
Abramowicz, Marc
Altomare, Daniele
Barkhof, Frederik
Berthier, Marcelo
Bieler, Melanie
Blennow, Kaj
Brayne, Carol
Brioschi, Andrea
Carrera, Emmanuel
Chételat, Gael
Csajka, Chantal
Demonet, Jean-François
Dodich, Alessandra
Dubois, Bruno
Frisoni, Giovanni B.
Garibotto, Valentina
Georges, Jean
Hurst, Samia
Jessen, Frank
Kivipelto, Miia
J. Llewellyn, David
McWhirter, Laura
Milne, Richard
Minguillón, Carolina
Miniussi, Carlo
Molinuevo, José Luis
Nilsson, Peter M.
Ranson, Janice M.
Ribaldi, Federica
Ritchie, Craig
Scheltens, Philip
Solomon, Alina
van der Flier, Wiesje
van Duijn, Cornelia
Vellas, Bruno
Visser, Leonie
-
Funding
Funding for this research was provided by:
Swiss National Science Foundation (IZSEZ0_193593)
- License Information
-
More Information
Article History
Received: 12 March 2021
Accepted: 26 August 2021
First Online: 11 October 2021
Change Date: 23 October 2021
Change Type: Update
Change Details: The paper was amended to add a DOI in references part of the Brain Health Services series.
Declarations
:
: Not applicable
: Not applicable
: GBF reports grants from Alzheimer Forum Suisse, Académie Suisse des Sciences Médicales, Avid Radiopharmaceuticals, Biogen, GE International, Guerbert, Association Suisse pour la Recherche sur l’Alzheimer, IXICO, Merz Pharma, Nestlé, Novartis, Piramal, Roche, Siemens, Teva Pharmaceutical Industries, Vifor Pharma, and Alzheimer’s Association; he has received personal fees from AstraZeneca, Avid Radiopharmaceuticals, Elan Pharmaceuticals, GE International, Lundbeck, Pfizer, and TauRx Therapeutics.KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.JLM is currently a full time employee of Lundbeck and has previously served as a consultant or at advisory boards for the following for-profit companies, or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, ProMIS Neurosciences.All other authors declare that they have no competing interests.
